CIFoundry
Back to Catalog
Oncology
FDA cleared

TumorSight Viz

Save to shortlist
SimBioSys

Last reviewed Oct 31, 2026 against the sources listed on this page · How we review

At a glance

TumorSight Viz is a cloud-based breast cancer imaging tool that converts DCE-MRI studies into interactive 3D models for preoperative planning.

FDA:
510(k) K251766 +2 more
Epic:
Not on record
Named users:
Not on record
Published study:
Not on record

Description

TumorSight Viz is a cloud-based breast cancer imaging tool that converts DCE-MRI studies into interactive 3D models for preoperative planning. It is used by breast cancer surgeons and clinicians to visualize tumor extent and review measurements such as tumor volume and distance to nearby anatomical features.

Breast Cancer3D VisualizationMRISurgical Planning

Quick answers

Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review

Is TumorSight Viz FDA cleared?
The public FDA database has 3 records that our team matched to TumorSight Viz. The most recent is 510(k) K251766 (TumorSight Viz), decided Jul 2025. Check that the cleared use matches how you plan to use it.FDA record K251766

Security & contracting

The maker has not reported these details yet. Ask the vendor directly during evaluation.

Workflow stage
Not reported
Integrations
Not reported
Data inputs
Not reported
Deployment
Not reported
Signs a BAA
Not reported
SOC 2 report
Not reported
HITRUST
Not reported
Evidence type
Not assessed

Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.

Who's using this

Organizations named in public announcements or by the developer. Inclusion is not an endorsement.

No public deployments found yet (checked Oct 2026). Using this tool? The maker can claim the listing to add customers.

Get weekly updates for Oncology

Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.

Sources

This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.

Website

FDA database records

  • K251766 · 510(k) · Jul 2025
    TumorSight Viz
  • K243189 · 510(k) · Oct 2024
    TumorSight Viz
  • K231130 · 510(k) · Dec 2023
    TumorSight Viz

Matched by our team from the public FDA database; checked Nov 10, 2026.

History (4)Show

Dated events on this listing's public record, newest first.

  1. Oct 31, 2026

    Added to CIFoundry

  2. Jul 8, 2025

    FDA 510(k) K251766 decision datesource

  3. Oct 25, 2024

    FDA 510(k) K243189 decision datesource

  4. Dec 26, 2023

    FDA 510(k) K231130 decision datesource

Developer

SimBioSys

Evaluating this tool?

Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.

Prepare evaluation packet

Checklist for your role: Admin · Physician · IT · Compliance

Compare similar tools →

Own this tool?

Claim this listing to update its details and connect with your audience.